Maxim Labkouski
Ahead of JP Morgan’s 2025 Healthcare Conference, scheduled to be held in a few days, Oppenheimer named five potential biotech buyout candidates on Friday, naming obesity drug developer Viking Therapeutics (NASDAQ: VKTX) in the list.
In addition to VKTX, Biegler
